Children with acute lymphoblastic leukemia (ALL) have an increased risk of obesity and short stature. To the authors' knowledge, data regarding patients treated on contemporary protocols without cranial irradiation are limited. METHODS: Changes in z scores for body mass index (BMI), height, and weight from the time of diagnosis to 5 years off therapy were evaluated using multivariable analysis in 372 children with ALL who were aged 2 to 18 years at the time of diagnosis and were enrolled on the St. Jude . Among patients who were of healthy weight/underweight at the time of diagnosis, those aged 2 to <10 years at diagnosis had a significantly higher risk of becoming overweight/obese during or after therapy compared with those aged ≥10 years (P = .001). Height z scores declined during treatment and improved after therapy. Being aged 2 to <10 years at the time of diagnosis, being of low-risk status, having a white blood cell count < 50 × 10 9 /L at the time of diagnosis, and having negative central nervous system disease were associated with significantly better improvements in z scores for height during the off-therapy period compared with being aged ≥10 years, being of standard-risk/high-risk status, having a white blood cell count ≥ 50 × 10 9 /L, and having positive central nervous system disease, respectively. CONCLUSIONS: The results of the current study demonstrate that obesity is prevalent, and height growth, especially in patients with identified risk factors, appears compromised. Multidisciplinary intervention should begin during induction therapy and continue during the off-therapy period. Cancer 2018;124:4248-4259.
INTRODUCTION
As a result of improved risk-directed treatment and supportive care, the survival rate for children with acute lymphoblastic leukemia (ALL) has improved dramatically to approximately 90%. 1 Childhood obesity is prevalent in the United States (17.0% of US children were reported to be obese from 2011-2014) 2 ; however, children with ALL are at an increased risk of becoming overweight or obese, [3] [4] [5] [6] which can result in substantial physical and psychosocial morbidity and further complicate other therapy-associated adverse effects, such as infections, osteopenia, and osteonecrosis. 3 Reductions in linear growth and final adult height are well-known complications of ALL treatment, especially that involving cranial irradiation, which can cause hypothalamic-pituitary dysfunction. [7] [8] [9] To the best of our knowledge, data regarding obesity and linear growth in children with ALL who are treated uniformly on a single contemporary protocol without cranial irradiation are limited.
It has been suggested that interventions to promote healthy body composition should be initiated during therapy. [10] [11] [12] However, to our knowledge, guidelines regarding the timing and nature of such efforts are lacking, and we have not conducted intervention trials at the study institution. To evaluate the appropriate timing and duration of an
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MATERIALS AND METHODS

Patients
Children and adolescents with ALL (those aged 1-18 years at the time of diagnosis) were enrolled on the Total XV protocol at St. Jude between 2000 and 2007. 13 Patients who died, experienced disease recurrence, received reintensification therapy because of refractory disease, or underwent a hematopoietic stem cell transplantation were censored at the time of the event. The study was approved by the St. Jude institutional review board.
Patient characteristics were recorded, including sex, age at the time of diagnosis (age 2 to <10 years vs ≥10 years), risk stratification (low risk [LR] vs standard risk/ high risk [SR/HR]), white blood cell count (WBC) at the time of diagnosis (<50 × 10 9 /L vs ≥50 × 10 9 /L), central nervous system (CNS) disease status (CNS-1 vs CNS-2, CNS-3, or traumatic lumbar puncture with blast cells), and immunophenotype (B-cell ALL vs T-cell ALL). Race was recorded based on genetic ancestry (black, white, Native American, or other) as determined by DNA single-nucleotide polymorphisms.
14 Because of the small numbers of patients in the Native American and "other" groups, the analysis of race was expressed as comparisons between black and white races only, although all races were incorporated into the mixed model.
Treatment
Total XV therapy lasted approximately 2.5 years for females and 3 years for males and consisted of 3 treatment phases: induction (6 weeks), consolidation (8 weeks) , and continuation (120 weeks for females and 146 weeks for males) (Fig. 1) . 13 All patients received prednisone at a dose of 40 mg/m 2 /day for 28 days during induction and dexamethasone at a dose of 8 mg/m 2 /day on days 1 to 8 and days 15 to 21 during reinduction I (continuation weeks 7-9) and reinduction II (weeks [17] [18] [19] . Five-day dexamethasone pulses (every 3-4 weeks) were administered during continuation therapy at a dose of 8 mg/m 2 /day for patients with LR status and 12 mg/ m 2 /day for SR/HR patients from continuation week 1 to week 100, except in the weeks of reinduction I and reinduction II. Depending on their risk and CNS status, patients received 13 to 25 intrathecal treatments without cranial irradiation. After completing therapy, patients were followed at least yearly.
BMI, Weight, and Height
Height and weight data were obtained from routine clinic visits at St. Jude at 16 time points for females and 17 time points for males: the start of induction (±3 days); day 19 of induction (±3 days); the end of induction (±7 days); continuation weeks 1, 7 (the start of reinduction I), 10, 17 (the start of reinduction II), and 21 (±7 days), as well as weeks 48, 96, 120 (the end of therapy for females), and 146 (the end of therapy for males) (±14 days); and every year thereafter (±180 days) until the patients were 5 years off therapy (Fig. 1) . A broader time range (±180 days) was allowed for data collection during the off-therapy period because patient scheduling preferences and appointment availability did not always align with the off-therapy anniversary, especially after 3 years of being off therapy, when patients transition to our survivorship clinic, which has different schedule availability. Each individual's height and weight data were checked for outlier values by first fitting a quadratic local regression polynomial to the data, using the "smooth" function with the "loess" method in MATLAB software (version R2017a; MathWorks Inc, Natick, Massachusetts). An outlier value was defined as a height with an absolute residual >5 cm or 15% or a weight with an absolute residual >10 kg or 25%. Outlier values were replaced with interpolated values, again using quadratic local regression polynomials and the remaining nonoutlier data. BMI was calculated as the weight in kilograms divided by the square of the height in meters. BMI, height, and weight data for patients aged 2 to 20 years were converted to age-adjusted and sexadjusted z scores using the SAS statistical program (SAS Institute Inc, Cary, North Carolina) for the Centers for Disease Control and Prevention (CDC) growth charts. 15 For patients aged >20 years and for final height analysis, z scores were calculated based on reference data for individuals aged 20 years. 10, 16 For BMI category (underweight, healthy weight, overweight, or obese), percentile criteria were used for patients aged 2 to 20 years and the actual BMIs were used for those individuals aged >20 years. The final height was defined when the growth velocity was <2 cm over a 12-month period after the completion of therapy. 17 Permanent loss of height was calculated as the difference between the predicted final height based on the height z score at the time of diagnosis and the actual final height. Short stature was defined as a height z score < -2. We also calculated z scores for participants in the National Health and Nutrition Examination Survey (NHANES) for 2005 to 2006 (those aged 2-19 years) using the CDC 2000 growth charts, and we used survey sampling methodology to calculate the means by age and sex. 15, 18 We then applied indirect standardization based on the distribution of age and sex in the study cohort.
Statistical Analysis
Changes in z scores for BMI, height, and weight between time points were evaluated using repeated measures, adjusting for the effects of baseline z scores, age, sex, ancestry, treatment risk, CNS status, WBC count at the time of diagnosis, and time. The correlation of z scores at each time point with those at diagnosis was examined using the Pearson correlation coefficient. The associations of z scores with clinical features at each time point were analyzed using the Wilcoxon rank sum test (for 2 groups) or the Kruskal-Wallis test (for >2 groups) in univariate analysis, and longitudinal data of z scores were then evaluated using a mixed model, with factors with P values <.1 at ≥2 time points in univariate analysis, as well as treatment risk, sex, race, baseline z scores, and time points. Risk factors for patients who were underweight or of healthy weight at the time of diagnosis becoming overweight or obese were evaluated using the chi-square test using clinical characteristics, and a multivariable logistic regression model was used for characteristics with P values <.1. Missing data and data for censored patients were not imputed in the current statistical analyses. P values were not adjusted for multiple comparisons.
RESULTS
Patient Characteristics
Of the 408 children with ALL who were enrolled on the St. Jude Total XV protocol, 10 with Down syndrome and 26 who were aged between 1 and 2 years at the time of diagnosis were excluded, leaving 372 children for study ( Longitudinal changes in the percentage of patients in each BMI category demonstrated the percentage of overweight/obese patients increasing and that of underweight patients decreasing over time (Fig. 2) . Although a broader time range (±180 days) was allowed for data collection during the off-therapy period, the percentages of patients beyond the 90-day point were as follows: 3.4% were 1 year off therapy, 5.2% were 2 years off therapy, 13.3% were 3 years off therapy, 21.0% were 4 years off therapy, and 24.6% were 5 years off therapy. There were very few outliers requiring interpolation (representing <0.7% of the data for height and <0.1% of the data for weight). Figure 3A and Supporting Table 1 show the longitudinal changes in the median BMI z score. The median BMI z score at all on-therapy and off-therapy time points, except day 19 of induction, was significantly higher than at , corresponding to the discontinuation of dexamethasone pulses after week 100. Figure 3B and Supporting Table 2 show the longitudinal changes in the median height z scores. From the time of diagnosis (median z score of 0.37), the median z scores for height decreased during ALL therapy (to -0.13 at week 120) and then improved during the off-therapy period (to 0.22 at 5 years off therapy), although they never improved to the levels noted at the time of diagnosis. After week 1, all median z scores for height were significantly lower than the score at the time of diagnosis (P ≤ .008 for all). The incidence of short stature, defined as a height z score <-2, increased from 2 of 372 patients (0.5%) at the time of diagnosis to 14 of 317 patients (4.4%) at week 120 (Fig. 3B) . Twenty-six patients had height z scores < -2 during or after therapy, and 24 patients were evaluable for follow-up. Seven patients were seen by the endocrinology department because of significant concerns regarding their growth velocity: 3 of the 7 underwent dynamic testing that ruled out growth hormone deficiency, 2 had normal screening plasma insulinlike growth factor 1 (IGF-1) levels, and 2 were observed without testing because of familial short stature (both reached final heights consistent with the mid-parental heights). Seventeen patients were not seen by endocrinology, and 12 experienced spontaneous improvements in their growth velocity (among these, 6 had normal IGF-1 levels and 6 were not tested) so that referral was not deemed necessary. For the remaining 5 patients, there was no information regarding their familial height or growth potential. Three of these patients had normal IGF-1 levels and 2 were not tested. None of the patients was treated with growth hormone.
The median z scores for weight in weeks 21, 48, and 96 and at 1 year off therapy and after were found to be significantly higher than the median score at the time of diagnosis (0.45) (P ≤ .041 for all) and increased during the off-therapy period ( Fig. 3C ) (see Supporting Table 3 Supporting Table 4 shows the significant correlations of the z scores for BMI, height, and weight at the time of diagnosis with subsequent values (P < .001 for all), although the correlations became less significant at the later time points.
Because obesity has become more of a problem in the general pediatric population since the growth curves were constructed in 2000, 2, 19 we estimated the z scores for BMI, height, and weight among participants in the NHANES for 2005 through 2006 (those aged 2-19 years) who were matched to our patient population by age and sex. The mean z scores ± the standard error for BMI, height, and weight were 0.33 ± 0.13, 0.23 ± 0.12, and 0.37 ± 0.13, respectively.
Clinical Characteristics Affecting BMI z Scores During and After Therapy
Supporting Table 5 shows the significant differences in the median BMI z scores for clinical characteristics at each time point, as determined by univariate analysis. In multivariable analysis (Fig. 4) (see Supporting Table 6 ), patients aged 2 to <10 years at the time of diagnosis had median BMI z scores between week 21 and 3 years off therapy that were significantly higher than those of patients aged ≥10 years at the time of diagnosis (P ≤ .033 for all) (Fig. 4A ). Median z scores in older patients declined from week 48 to the end of therapy but increased during the off-therapy period.
Median z scores for BMI were higher for LR patients than for SR/HR patients in weeks 7, 10, and 17 (P ≤ .005 for all) (Fig. 4B) ; higher for males than for females on day 19, at the end of induction, and in week 10 (P ≤ .025 for all) (Fig.  4C) ; and higher for black patients than for white patients at the end of induction and in weeks 1 and 10 (P ≤ .043 for all) (Fig. 4D) . However, these differences disappeared later in the off-therapy period.
We also evaluated risk factors in patients who were of healthy weight or underweight at the time of diagnosis but became overweight or obese during or after therapy (Table 2 ). Multivariable analysis demonstrated that patients aged 2 to <10 years at the time of diagnosis had a significantly higher risk of becoming overweight/obese than those aged ≥10 years (P = .001).
Clinical Characteristics Affecting Height z Scores During and After Therapy
The results of univariate analysis of median z scores for height with respect to clinical characteristics are shown in Supporting Table 7 . The results of multivariable analysis are shown in Figure 5 and Supporting Table 8 . Patients aged ≥10 years at the time of diagnosis had median height z scores at the end of induction and in continuation weeks 1 to 21 that were significantly higher than those of patients aged 2 to <10 years at the time of diagnosis (P ≤ .038 for all); however, the median height z scores at 5 years off therapy were found to be significantly higher for patients aged 2 to <10 years at the time of diagnosis than for patients aged ≥10 years at the time of diagnosis (P = .011) (Fig. 5A) . Median z scores for height were higher for LR patients than for SR/HR patients in weeks 17, 21, 48, and 146 and at 1 to 3 years off therapy (P ≤ .024 for all) (Fig. 5B) . At 3 to 5 years off therapy, the median z scores for height among patients with WBCs < 50 × 10 9 /L at the time of diagnosis were higher than those of patients with WBCs ≥ 50 × 10 9 /L at the time of diagnosis (P ≤ .018 for all) (Fig. 5C ). Compared with patients with CNS disease (CNS-2, CNS-3, or a traumatic lumbar puncture with blast cells), those with CNS-1 status had significantly higher median height z scores at 3 years off therapy (P = .029) (Fig. 5D ). Median z scores for height were higher for males than for females in weeks 96 and 120 (P ≤ .009 for all) and higher for white patients than for black patients at 2 to 4 years off therapy (P ≤ .027 for all). Of 106 patients aged ≥10 years at the time of diagnosis, 68 had reached their final height after completing therapy; the median z scores at final height (-0.31) were significantly lower than those at the time of diagnosis (0.28) (P = .003) (see Supporting Fig. 1 ). The median permanent loss of height and height z score in female patients (30 patients) were 1.90 cm (range, -3.00 cm to 12.05 cm) and 0.29 (range, -0.46 to 1.89), respectively, and the corresponding values in male patients (38 patients) were 2.13 cm (range, -8.00 cm to 25.50 cm) and 0.30 (range, -1.13 to 3.56), respectively. When analysis was limited to patients aged 10 to 15 years at the time of diagnosis, the median permanent loss of height and its z score in female patients (19 patients) were 4.60 cm (range, -1.80 cm to 12.05 cm) and 0.71 (range, -0.28 to 1.89), respectively, and the corresponding values in male patients (25 patients) were 5.75 cm (range, -8.00 cm to 25.50 cm) and 0.81 (range, -1.13 to 3.56), respectively.
Clinical Characteristics Affecting Weight z Scores During and After Therapy
The results of univariate analysis are shown in Supporting Table 9 . In multivariable analysis (see Supporting Fig. 2 ) (see Supporting Table 10 ), patients aged 2 to <10 years at the time of diagnosis had median weight z scores in week 7 that were significantly lower than those of patients aged ≥10 years at the time of diagnosis (P = .025); however, from week 96 to 1 year off therapy, patients aged 2 to <10 years at the time of diagnosis had median z scores for weight that were higher than those of patients aged ≥10 years at the time of diagnosis (P ≤ .007 for all) (see Supporting Fig. 2A ). Median z scores for weight were higher for LR patients than for SR/HR patients in weeks 7, 10, 17, and 146 and at 4 years off therapy (P ≤ .048 for all) (see Supporting Fig. 2B ). Median z scores for weight were higher for males than for females at the end of induction and in weeks 10, 21, and 120 (P ≤ .047 for all) (see Supporting Fig. 2C ) and were Abbreviations: CNS, central nervous system; WBC, white blood cell count. a Multivariable analysis was performed to determine the independent effect of each factor that had a P value <.10 in univariate analysis. b Germline samples for ancestry analysis were not available.
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DISCUSSION
By analyzing data acquired at multiple time points, we studied the longitudinal changes in BMI, height, and weight and their associations with other characteristics of pediatric patients with ALL who were treated with a single contemporary regimen without cranial irradiation. Median BMI z scores started to increase during induction therapy and remained elevated after the completion of chemotherapy. Median z scores for height decreased during therapy and then improved during the off-therapy period; however, they remained low in patients aged ≥10 years at the time of diagnosis, in those with SR/HR status, in those with an initial WBC ≥ 50 × 10 9 /L, and in those with positive CNS disease. Median z scores for weight were relatively stable during therapy, except for increases during intensive glucocorticoid treatment; however, these z scores increased in the off-therapy period. The median BMI z scores increased during therapy because of significant decreases in the median z scores for height and moderate increases in the median z scores for weight, whereas the increases in median BMI z scores during the off-therapy period primarily were due to increases in the median weight z scores. When we estimated the z scores for BMI, height, and weight in the recent population, the patients still demonstrated comparatively higher z scores for BMI and weight, especially between continuation weeks 21 and 96 and during the off-therapy period.
Previous studies of children and adolescents with ALL demonstrated increases in BMI during and after treatment, regardless of whether cranial irradiation was used, without recovery to the baseline value. 4, 5 Although the BMI z scores of the patients in the current study declined during the first 19 days of induction therapy, possibly because of leukemia-related illness, they increased significantly in the latter 4 weeks of induction therapy, which is when BMI started to increase. Another significant increase in BMI occurred during reinduction therapy II. Patients received intensive glucocorticoid therapy in these periods. There were significant decreases in BMI noted between continuation weeks 96 and 120 after the discontinuation of glucocorticoid pulses. Glucocorticoid treatment increases energy intake, stimulates cellular lipid accumulation by inducing differentiation of preadipocytes to adipocytes, and increases insulin resistance. [20] [21] [22] Many patients with ALL also exhibit an imbalance between their caloric intake from an unhealthy diet and their energy expenditure that reflects a sedentary lifestyle due to chemotherapy-related fatigue and parental permission, 23, 24 leading to increased BMI and weight z scores. Further significant increases in BMI z scores due to weight gain were noted after patients completed therapy. It is likely that unhealthy dietary and behavioral habits established over 2.5 years of treatment persist after the completion of therapy. 25 In the multivariable analysis of BMI z scores, scores for LR, male, and black patients during the early phase of therapy were higher than those for SR/HR, female, and white patients, respectively. Patients aged 2 to <10 years at the time of diagnosis had higher BMI z scores compared with patients aged ≥10 years at the time of diagnosis from the continuation therapy phase to the early off-therapy period. Patients in this age group who were of healthy weight/underweight had a higher risk of becoming overweight/obese during or after therapy compared with older patients. Younger age was associated with obesity in several studies. 26, 27 LR patients receive less intensive therapy compared with SR/HR patients. Some studies have suggested that female patients are at a higher risk of becoming overweight/obese compared with male patients, whereas other studies found no such difference between the sexes. 4 A meta-analysis demonstrated that the BMI of female survivors increased during the off-therapy period, 5 which may explain why off-therapy BMI z scores were similar for male and female survivors in the current study. The higher BMI z scores observed for black patients compared with white patients have been reported previously. 2 However, these observed differences disappeared later in the off-therapy period, suggesting that BMI gain after therapy completion is prevalent in survivors of ALL regardless of their clinical characteristics.
We evaluated the longitudinal changes in height z scores, which decreased during therapy and improved after its completion. Previous studies have demonstrated that patients receiving chemotherapy without cranial irradiation can catch up with respect to their height z scores after completing therapy. 9, 28 It is important to note that we found that the median height z scores of patients aged ≥10 years at the time of diagnosis were higher than those of patients aged 2 to <10 years at the time of diagnosis until the early phase of continuation therapy but demonstrated no improvement after therapy, and at 5 years off therapy had become lower than those of patients aged 2 to <10 years at the time of diagnosis. Older patients would have been in the midst of their growth spurt at the time of diagnosis and early in their treatment, but chemotherapy could have slowed this process until they attained their final height, which might have led to weight and BMI gain during the off-therapy period. The changes in the median height z score from diagnosis to weeks 120 and 146 were -0.50 and -0.56, respectively. Although the changes at other time points were smaller than these, the permanent loss of height in patients aged 10 to 15 years at the time of diagnosis was approximately 5 cm. We consider these findings to be clinically significant.
Height z scores also were lower in SR/HR patients and in those with initial WBCs ≥ 50 × 10 9 /L. Intensive therapy given to SR/HR patients, such as high doses of methotrexate, doxorubicin, cyclophosphamide, or cytarabine, would have affected their linear growth. Previously obtained data have indicated that children in whom ALL was diagnosed before the age of 4 years and whose treatment included cranial irradiation had significant linear growth deficits. 27 However, younger patients, especially LR patients, experienced a growth spurt during the off-therapy period, and their height z scores then became comparable to those at diagnosis if they were treated without cranial irradiation. We confirmed that the height z scores of patients who were older at the time of diagnosis were lower than at diagnosis when these patients attained their final height, but it is important to confirm that younger patients have z scores at their final heights that are comparable to those at diagnosis. Although it was significant at 3 years off therapy only, CNS involvement at the time of diagnosis was associated with lower z scores for height. This is possibly due to the frequent intrathecal chemotherapy received by patients with CNS disease or to the direct effect of leukemia involvement in the CNS on linear growth. Further study is needed to confirm this finding. Previous studies regarding height included patients treated with multiple protocols and some who received cranial irradiation. Therefore, we believe our data regarding patients treated with a single frontline ALL regimen without cranial irradiation are useful, because more patients with ALL are being treated without irradiation.
We recommend that interventions to prevent obesity be introduced for all patients during induction therapy because excessive weight gain early in treatment is unlikely to be reversed. Evidence-based obesity prevention guidelines recommend using motivational interviewing to work with the patient and family to establish goals for behavioral changes such as decreasing the consumption of sugar-sweetened beverages and decreasing screen time. 29 Initial interactions during induction would focus on introducing concepts and delivering education to set the stage for future lifestyle changes. Great care would be taken to meet the patient/family's interest in "where they are" in terms of readiness for change. 29, 30 In a survey of
Cancer November 1, 2018 parents of children undergoing therapy for ALL, nearly one-third of them recommended that these conversations begin during induction (unpublished data). Because of the significant association between values at the time of diagnosis and those at subsequent follow-up, patients exhibiting obesity and/or short stature at the time of diagnosis require particular attention. Such interventions should involve a multidisciplinary team of oncologists, nurses, dietitians, physical therapists, psychologists, and endocrinologists, 31 and they must continue during the off-therapy period. Such efforts can focus on modifiable behaviors, using a family-centered approach to support healthy nutritional intake and reduce sedentary behavior. 32 For patients with a linear growth deficit, especially those with identified risk factors (older age, SR/HR status, higher WBCs, and/or CNS involvement), endocrine evaluation for growth hormone deficiency should be considered. It also is important to examine whether reducing the cumulative doses of glucocorticoids or other conventional chemotherapeutic agents and using emerging therapeutic approaches, such as molecularly targeted agents or immune therapy, can reduce the toxicities without compromising the antileukemia effects. 1 The current study is strengthened by its inclusion of only those patients treated with a single contemporary regimen without cranial irradiation. Multiple time points corresponding to different phases of therapy were evaluated to identify interval changes in the z scores of 3 parameters. BMI is not the best indicator of body composition but nevertheless frequently is used as a cost-effective, easily attainable, and clinically feasible anthropometric measurement. We did not perform routine dual-energy x-ray absorptiometry scans or waist circumference measurements, which can indicate obesity missed by BMI measurements.
In children with ALL, BMI z scores appear to increase significantly because of decreases in height z scores and increases in weight z scores during therapy, and mainly because of increases in weight z scores after the completion of therapy. Neither BMI nor weight z scores are reported to recover to baseline. Although height z scores improve after the completion of chemotherapy, patients aged ≥10 years at the time of diagnosis, with SR/ HR status, with an initial WBC ≥ 50 × 10 9 /L, and/or with positive CNS disease demonstrate less improvement compared with other patients. Accordingly, all patients should be monitored for excess weight gain and linear growth and be exposed to multidisciplinary healthy lifestyle promotions, beginning during induction therapy. These efforts should continue even during the off-therapy period.
